Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer

Autor: Elif Şenocak Taşçı, Başak Oyan, Özlem Sönmez, Arda Ulaş Mutlu, Muhammed Mustafa Atcı, Abdullah Sakin, İrem Öner, Havva Yeşil Çınkır, Melek Karakurt Eryılmaz, Dilek Çağlayan, Onur Yazdan Balçık, Nail Paksoy, Senem Karabulut, Derya Kıvrak Salim, Cemil Bilir, Miraç Özen, Melike Özçelik, Ali Arıcan, Baran Akagündüz, Ali İnal, Dinçer Aydın, Leyla Özer, Ahmet Gülmez, Nazım Serdar Turhal, Selin Aktürk Esen, Efnan Algın, Sinem Akbaş, Yakup İriağaç, Teoman Şakalar, Çağlar Ünal, Özlem Er, Şaban Seçmeler, Mustafa Bozkurt

Publikováno v: BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)

Abstract Background The optimal treatment for metastatic colorectal cancer (mCRC) after the second line is still controversial. Regorafenib has been the standard of care in this setting as it improved overall survival (OS) compared to placebo. In rea

Externí odkaz: https://doaj.org/article/7d19cca4236d429b8424cc6bef6070f5

Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Autor: Cengiz Karacin, Berna Oksuzoglu, Ayşe Demirci, Merve Keskinkılıç, Naziyet Köse Baytemür, Funda Yılmaz, Oğuzhan Selvi, Dilek Erdem, Esin Avşar, Nail Paksoy, Necla Demir, Sema Sezgin Göksu, Sema Türker, Ertuğrul Bayram, Abdüssamet Çelebi, Hatice Yılmaz, Ömer Faruk Kuzu, Seda Kahraman, İvo Gökmen, Abdullah Sakin, Ali Alkan, Erdinç Nayır, Muzaffer Uğraklı, Ömer Acar, İsmail Ertürk, Hacer Demir, Ferit Aslan, Özlem Sönmez, Taner Korkmaz, Özde Melisa Celayir, İbrahim Karadağ, Erkan Kayıkçıoğlu, Teoman Şakalar, İlker Nihat Öktem, Tülay Eren, Enes Erul, Eda Eylemer Mocan, Ziya Kalkan, Nilgün Yıldırım, Yakup Ergün, Baran Akagündüz, Serdar Karakaya, Engin Kut, Fatih Teker, Burçin Çakan Demirel, Kubilay Karaboyun, Elvina Almuradova, Olçun Ümit Ünal, Abdilkerim Oyman, Deniz Işık, Kerem Okutur, Buğra Öztosun, Burcu Belen Gülbağcı, Mehmet Emin Kalender, Elif Şahin, Mustafa Seyyar, Özlem Özdemir, Fatih Selçukbiricik, Metin Kanıtez, İsa Dede, Mahmut Gümüş, Erhan Gökmen, Arzu Yaren, Serkan Menekşe, Senar Ebinç, Sercan Aksoy, Gökşen İnanç İmamoğlu, Mustafa Altınbaş, Bülent Çetin, Başak Oyan Uluç, Özlem Er, Nuri Karadurmuş, Atike Pınar Erdoğan, Mehmet Artaç, Özgür Tanrıverdi, İrfan Çiçin, Mehmet Ali Nahit Şendur, Esin Oktay, İbrahim Vedat Bayoğlu, Semra Paydaş, Adnan Aydıner, Derya Kıvrak Salim, Çağlayan Geredeli, Tuğba Yavuzşen, Mutlu Doğan, İlhan Hacıbekiroğlu

Publikováno v: BMC Cancer, Vol 23, Iss 1, Pp 1-10 (2023)

Abstract Background There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment

Externí odkaz: https://doaj.org/article/042edc2981bf4d52a01526b7a7c03f4f

First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer

Autor: Selin Aktürk Esen, Yakup Ergun, Cihan Erol, Rukiye Arikan, Muhammed Muhiddin Er, Muhammed Mustafa Atci, Atakan Topçu, Gökhan Uçar, Baran Akagündüz, Musa Bariş Aykan, Miraç Özen, Naziyet Köse Baytemur, Melike Özçelik, Elif Şahin, Denizcan Güven, Serkan Menekşe, Naziye Ak, Fatih Teker, Engin Kut, Teoman Şakalar, Özkan Alan, Turgut Kaçan, Nazim Serdar Turhal, Saadettin Kiliçkap, Sema Türker, Mehmet Ali Nahit Şendur, Osman Köstek, Mustafa Karaağaç, Abdullah Sakin, Haci Mehmet Türk, Dilek Çağlayan, Şener Cihan, Yusuf Açikgöz, Doğan Uncu

Publikováno v: Biomolecules & Biomedicine, Vol 22, Iss 5 (2022)

Fluoropyrimidine+cisplatin/oxaliplatin+trastuzumab therapy is recommended for the first-line treatment of HER2-positive metastatic gastric adenocarcinoma. However, there is no comprehensive study on which platinum-based treatment should be preferred.

Externí odkaz: https://doaj.org/article/76c42bc31695447ca49b70652deb5b62

Clinical and Pathological Characteristics of Patients with High-Risk Breast Cancer Based on BRCA Mutation Profiles: A Retrospective Study

Autor: Muhammed Mustafa Atcı, Çağlayan Geredeli, Seval Ay, Abdullah Sakin, Biray Ertürk, Şaban Seçmeler, Serdar Arıcı, Ruhper Çekin, Nurgül Yaşar, Orçun Can, Şener Cihan, Mahmut Gümüş

Publikováno v: European Journal of Breast Health, Vol 17, Iss 2, Pp 123-127 (2021)

Objective:This study aimed to determine the differences in clinicopathological features of Turkish patients with high-risk breast cancer based on the mutation status of two breast cancer susceptibility genes (BRCA1/2) .Materials and Methods:This stud

Externí odkaz: https://doaj.org/article/8acb16f0797b415286c35d3e43a5b7c2

Factors affecting survival in esophageal squamous cell carcinoma: Single-center experience

Autor: Abdullah Sakin, Yonca Yilmaz Urun, Suleyman Sahin, Muhammed Mustafa Atici, Serdar Arici, Caglayan Geredeli, Nurgul Yasar, Cumhur Demir, Sener Cihan

Publikováno v: İstanbul Kuzey Klinikleri, Vol 7, Iss 3, Pp 267-274 (2020)

OBJECTIVE: Squamous cell esophageal cancer (ESCC) is a highly fatal malignancy. This study aims to investigate the factors affecting survival in patients with metastatic and non-metastatic ESCC. METHODS: Between 2008 and 2016, 107 patients with ESCC

Externí odkaz: https://doaj.org/article/f3017bc32f054c85b6e2c3c9b423e7c0